ArticleESMO open2026

Abemaciclib plus endocrine therapy in HR-positive, HER2-negative high-risk early breast cancer: efficacy in nodal subgroups.

J Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.